Skip to content

Author

Talha Badar

We have 2 of 265 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

XmAb18968 is safe and tolerable with encouraging preliminary efficacy, supporting further investigation of CD38 targeting therapies in this setting, and further investigation of CD38 targeting therapies in this setting is supported.

G. S. Guru Murthy, B. Shah, Talha Badar et al. · 0 citations
Review Open access Aug 2026

Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy

Looking ahead, menin inhibitors may increasingly be incorporated into earlier lines of therapy, used as maintenance following allogeneic stem cell transplantation, and integrated into treatment approaches guided by measurable residual disease and evolving patterns of drug resistance.

Tina Y. Zhang, Shyam A. Patel, Talha Badar · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.